The Dutch Court of First Instance has found in favour of the taxpayer in a case involving indirect rebates paid to pharmaceutical companies. In essence, the court granted a refund of VAT to a pharmaceutical company based on the CJEU Boehringer case (C-462/16), although the pharmaceutical company was not obliged to grant the rebates under national law. Although the case was concerned with price arrangements with the Minister of Health, Welfare and Sport, it is possible that the same rationale could be applied to other rebate schemes, such as rebate arrangements between pharmaceutical companies and insurance companies.Continue reading VAT refund due to taxpayer on pharmaceutical rebates
Dear pharma & life sciences colleagues,
It was a pleasure to welcome you to our webinar: PwC Pharma & Life Sciences Webinar: COVID-19 impact on the ITX and regulatory DNA.
Attached below you can download the presentation.Continue reading PwC Pharma & Life Sciences Webinar: COVID-19 impact on the ITX and regulatory DNA
Do you know how healthy the value chain of your company is? Let’s have a look at some key questions in the pre- and post-marketing authorization life cycle of pharmaceuticals:
My recommendation on your next steps:
Choose a holistic approach in order to assess and possibly optimise the health of your value chain (tax, legal, regulatory, operational, digital etc.).
Use “scientific” out of the box thinking, innovation and an efficient delivery model as the tools to success.
Happy to discuss.
Have a nice summer day.